AroCell announces today that the European Patent Office (EPO) has issued a Decision to grant for the patent application No. 19 163 949.1 and entitled “Monoclonal anti-TK1 antibodies“, which will be published on 16 September 2020.
The patent application relates to AroCells proprietary monoclonal antibodies used for determining the Thymidine kinase 1 concentration in serum samples. These antibodies are used in the AroCell TK 210 ELISA kit.
“We are thrilled that we got a decision to grant for this patent in Europe. This means that the chance is high for the patent to be granted in the near future. This will reinforce our patent position in Europe and increase AroCells attractiveness as a business partner. We will continue to develop our portfolio of proprietary assets to further expand its business opportunities and to support our product AroCell TK 210 ELISA,” says Michael Brobjer, CEO AroCell.